Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD-1 Antibody Armored γδ T Cells in Malignant Meningioma
NCT07172178Phase 1Not yet recruiting
- Sponsor
- Nanjing Medical University
- Start
- Oct 2025
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies, Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of gamma-delta T-PD-1 antibody in meningioma, sponsored by Nanjing Medical University. Primary endpoints: Incidence of Adverse Events at 96 weeks, Dose Limiting Toxicity at 96 weeks and 1 more. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
gamma-delta T-PD-1 antibody
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT07172178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07172178.